Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.